目的：初步评估XEN凝胶引流管植入术在难治性青光眼治疗中的疗效及安全性。方法：回顾性分析2021-09/2022-01于北京大学第三医院行XEN凝胶引流管植入术的难治性青光眼患者10例11眼的临床资料，术后随访8～12mo，观察眼压及降眼压药物使用等情况，评估手术疗效。结果：纳入患者术前最高眼压为21～55(中位数35)mmHg，末次随访时眼压为10～40(中位数15)mmHg。术前使用降眼压药物2～4(中位数4)种，末次随访时使用降眼压药物0～4(中位数0)种。末次随访时，手术成功8眼，失败3眼。结论：XEN凝胶引流管植入术是治疗难治性青光眼安全且较为有效的手术方式。

AIM: To preliminarily evaluate the efficacy and safety of XEN drainage tube implantation in the treatment of refractory glaucoma.METHODS: The clinical data of 10 patients(11 eyes)with refractory glaucoma who underwent XEN gel drainage tube implantation in Peking University Third Hospital from September 2021 to January 2022 were retrospectively analyzed. All patients were followed-up for 8-12mo after surgery, the intraocular pressure(IOP)and the use of IOP lowering medication were observed, and the effect of the surgery was evaluated.RESULTS: The highest IOP was 21-55(median 35)mmHg before surgery and 10-40(median 15)mmHg at the last follow-up. There were 2-4(median 4)kinds of IOP lowering drugs before operation and 0-4(median 0)kinds of IOP lowering drugs at the last follow-up. Up to the last follow-up, the surgery was successful in 8 eyes and unsuccessful in 3 eyes.CONCLUSION: Implantation of XEN gel drainage tube is a safe and effective method for the treatment of refractory glaucoma.

国家自然科学基金资助项目(No.81970798)